# OnCo record vaginal-oestrogen-after-breast-cancer (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/vaginal-oestrogen-after-breast-cancer/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "vaginal-oestrogen-after-breast-cancer" ;
  schema:name "Vaginal oestrogen after breast cancer: what the evidence says, and where it disagrees"@en ;
  schema:description "Vaginal dryness and painful sex after cancer treatment are common, lasting and under-treated. Low-dose vaginal oestrogen is the usual answer outside cancer, and for women on an aromatase inhibitor the guidance disagrees: American and British bodies read the same cohort studies differently. A reader deserves to be told that rather than given one confident answer."@en ;
  schema:url <https://onco.cc/technologies/vaginal-oestrogen-after-breast-cancer/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Genitourinary_syndrome_of_menopause> ;
  schema:citation <https://doi.org/10.1093/annonc/mdj127>, <https://doi.org/10.1093/jnci/djac112>, <https://doi.org/10.1001/jamaoncol.2023.4508>, <https://doi.org/10.1016/j.ctrv.2025.102880>, <https://doi.org/10.1097/GME.0000000000001609>, <https://doi.org/10.1001/jamainternmed.2018.0116>, <https://doi.org/10.1007/s00520-017-3878-2>, <https://doi.org/10.1001/jama.2021.14892>, <https://doi.org/10.1097/AOG.0000000000001351>, <https://thebms.org.uk/publications/consensus-statements/> ;
  onco:status "established" ;
  onco:tag "rejuvenation", "survivorship", "evidence:moderate" ;
  onco:related <https://onco.cc/ideas/idea-moon-sexual-health-as-toxicity-domain/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/ovarian/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/>, <https://onco.cc/fronts/hormonal/> ;
  onco:technologies <https://onco.cc/technologies/menopause-after-cancer-treatment/>, <https://onco.cc/technologies/sexual-function-after-cancer/>, <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/technologies/survivorship-care-plan/> ;
  onco:drugs <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/anastrozole/>, <https://onco.cc/drugs/exemestane/>, <https://onco.cc/drugs/tamoxifen/> ;
  onco:terms <https://onco.cc/terms/menopause-after-chemotherapy-breast/>, <https://onco.cc/terms/aromatase-inhibitor/>, <https://onco.cc/terms/late-effects/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> .